Novartis, CH0012005267

Novartis stock: Nov. 25 CFO call follows 5% sales outlook

Published on 11/22/2026 at 18:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis stock has an analyst event scheduled for Wednesday, November 25. Investors will focus on the company's longer-term growth framework.

Novartis events and growth outlook

  • Novartis has scheduled an online Berenberg CFO Call series for Wednesday, November 25.
  • Management set a currency-adjusted sales CAGR target through 2031 in its November 19 investor update.
Novartis, CH0012005267, Illustration mit AI erstellt.

Novartis stock traded at 137.96 euros on Lang & Schwarz at 17:59 CET on Sunday, November 22. The company is scheduled to take part in an online Berenberg CFO Call series on Wednesday, November 25, according to its official event calendar.

Analyst call follows growth update

The call comes after Novartis announced on November 19 that it projects a 5% currency-adjusted sales compound annual growth rate through 2031. The company's investor-relations page also describes sustained mid-single-digit growth over the long term.

For investors, the November 25 discussion is the next scheduled company event in the week ahead. Its relevance lies in the opportunity for management to discuss the long-term sales framework and the operating priorities behind it. The event calendar lists no earnings release in the week; Novartis has scheduled its 2026 financial results for February 3, 2027.

What investors should watch

The key issue is whether management provides further detail on the growth framework, including the areas expected to support sales beyond the current reporting cycle. The November 19 update gives the company a longer planning horizon, while the CFO call offers a nearer-term investor discussion.

Novartis stock at a glance

  • Company: Novartis AG
  • ISIN: CH0012005267
  • Stock price: 137.96 euros on Lang & Schwarz, Sunday, November 22, 2026, at 17:59 CET
  • Upcoming event: Berenberg CFO Call series, Wednesday, November 25, 2026
  • Growth outlook: 5% currency-adjusted sales CAGR through 2031

European pharmaceutical shares will remain sensitive to company outlooks and regulatory developments; see the latest SMI market reports.

More news and analysis are available on Novartis stock.

Disclaimer...
en | CH0012005267 | NOVARTIS | boerse | 70544704 | bgmi